RPRX Royalty Pharma plc Insider Trading

EVP Christopher Hite sells 130,000 shares ($7.3M) at $56.50 avg on 2026-06-30, reducing stake to 40,000 shares via 10b5-1 plan

Christopher Hite, EVP & Chairman of Partnering at Royalty Pharma, executed 4 separate sales totaling 130,000 shares for $7,345,470.79 ($7.3M) on 2026-06-30, with a blended average price of $56.50 per share. This sale represents a -76.5% reduction in his holdings, from 170,000 shares to 40,000 shares post-transaction. The sales were conducted pursuant to a pre-arranged 10b5-1 trading plan adopted on 2026-03-20, indicating the transactions were scheduled and not discretionary in nature. At current price of $57.77, the stock is at -0.0% from its 52-week high of $57.80, having appreciated +7.0% over 30 days and +18.9% over 90 days, and the company reports strong fundamentals with net income of $294,690,000.00 against revenue of $630,576,000.00 in the latest quarter.

Christopher Hite sells 150,000 shares (21.1% reduction) for $8,159,276.82 via scheduled 10b5-1 plan

Christopher Hite, who was then EVP & Chairman, Partnering at Royalty Pharma, executed two separate sales totaling 150,000 shares (150.0K shares) for $8,159,276.82 on 2026-06-23 under a pre-arranged 10b5-1 trading plan adopted on 2026-03-20. The sales reduced his holdings from 709,399 shares to 559,399 shares, representing a -21.1% reduction in his position. As a scheduled transaction under Rule 10b5-1, this sale was not discretionary and therefore does not reflect current decision-making about the stock's direction or his conviction level at the time of filing.

CFO Terrance P. Coyne sold entire 64.4K share position in RPRX for $3.5M under pre-arranged 10b5-1 plan

Terrance P. Coyne, EVP & CFO, sold 64,399 shares of Royalty Pharma plc at $53.98 on 2026-05-26, liquidating his complete shareholding. This transaction was executed pursuant to a pre-arranged 10b5-1 trading plan adopted on 2026-02-24, meaning the sale was scheduled rather than discretionary. At the time of sale, RPRX traded at $53.98 against a current price of $54.48 and a 52-week high of $54.74, placing the transaction near the high end of the range. Coyne's prior trades at RPRX show mixed post-sale price performance: five preceding sales at this ticker yielded 30-day returns ranging from +2.4% to +9.2% and 90-day returns from +8.4% to +18.5%, while his broader cross-ticker track record across 20 prior sells averaged +7.0% 30-day and +16.6% 90-day returns. The company's fundamentals remain solid with $630.6M quarterly revenue, $294.7M net income, and +5.1% annual revenue growth, though the P/E of 25.58 reflects a mature valuation. The complete exit by a top finance executive warrants attention given his prior history at this ticker, though the scheduled nature of the trade precludes timing-based inference.

CFO Terrance Coyne sells nearly all RPRX shares in dual-tranche sale worth $1.73M near 52-week highs.

Coyne Terrance P., the company's Chief Financial Officer, liquidated his entire equity stake in Royalty Pharma across two transactions, divesting over $1.7 million in total value. The timing is noteworthy: the stock has rallied significantly in recent months and is currently trading near its 52-week highs, which is the opposite pattern from typical insider confidence-driven sales that usually occur during weakness or consolidation. Royalty Pharma is a profitable, revenue-growing business with solid fundamentals, so the sale doesn't signal financial distress at the company level. However, a CFO liquidating 100% of personal holdings at elevated valuations—rather than trimming positions gradually or during dips—suggests either portfolio rebalancing, estate planning, or a preference to reduce exposure at favorable pricing. This complete exit warrants monitoring to see whether other insiders follow suit or if the CFO's sales represent an isolated tax or personal liquidity event.

CFO Coyne sells 34,791 shares (34.8K) at $48.33 for $1.7M, reducing RPRX stake by -51.4%

CFO Terrance P. Coyne executed 2 separate sales totaling 34,791 shares for $1,681,511.66 at $48.33 on April 1, 2026, reducing his holdings from 67,707 to 32,916 shares. This represents a -51.4% reduction in his position. The sales occurred at the current market price of $48.57, at the 52-week high, following a 90-day gain of +25.0% in the stock. His cross-ticker track record shows a 90d well-timed rate of 0.00%, and his prior 5 trades at RPRX showed modest 30-day gains (+3.1% to +3.9%) with only recent 30-day outcomes measurable; no 90-day outcomes are yet available for comparison at this ticker. The scale of the reduction and proximity to the 52-week high merit monitoring, though the pattern against his historical cross-ticker timing record offers limited predictive signal.

CFO Terrance P. Coyne sold 34,791 shares of RPRX at $45.53 on 2026-03-23 for $1,583,989.00

Coyne, EVP & CFO, executed two separate sales totaling 34,791 shares (34.8K shares) at $45.53, reducing his holdings by 44.2% from 78.7K to 43.9K shares. The sales occurred near the stock's 52-week high of $47.48 (current price $47.03), with the stock up 3.4% over 30 days and 19.8% over 90 days—a period of sustained positive performance. His cross-ticker track record shows 20 prior sells with a 90-day well-timed rate of 0.00%, indicating his historical sell decisions have not preceded price declines; conversely, the average 90-day return of +17.5% after his prior sells suggests the stock typically rises following his exits. At RPRX specifically, four recent sales on 2026-03-02 lack measurable outcomes, while an earlier sale on 2026-02-23 showed a 30-day return of +3.8%, continuing the pattern of positive returns after his sales at this ticker.

CFO Coyne sells 34,791 shares (43.2% reduction) for $1.6M at $46.78 avg, stock near 52-week high

Terrance P. Coyne, EVP & CFO of Royalty Pharma, executed 4 separate sales on 2026-03-02 totaling 34,791 shares for $1,627,533.79, reducing his position from 80,552 to 45,761 shares. The blended average price of $46.78 aligns closely with the current price of $47.43 and comes within 0.1% of the 52-week high of $47.48, suggesting the sales occurred near the stock's peak valuation. This follows a pattern of recent same-ticker selling activity (5 prior sales at RPRX in early February 2026), and occurs in a stock posting strong near-term momentum: 30-day return of +12.0% and 90-day return of +21.2%. The 43.2% reduction in Coyne's holdings represents a material decrease in personal exposure to the company, though his cross-ticker track record shows prior sells have not been well-timed (90d well-timed rate of 0.00%, with average 90d return post-sell of +17.2%), meaning historically his sales have preceded further gains rather than declines.

CFO Coyne sells 34.8K shares ($1.6M) at RPRX, reducing stake 42.2%; fifth consecutive sell in 3 weeks

Terrance P. Coyne, EVP & CFO, executed two separate sales on 2026-02-23 totaling 34,791 shares for $1,576,606.35 at $45.32, reducing his holdings from 82,427 shares to 47,636 shares (a -42.2% reduction). This sale is notably part of a pattern: the SAME-TICKER HISTORY shows five prior transactions at RPRX—three sells on 2026-02-03, two on both 2026-02-04 and 2026-02-02—all clustered within the preceding three weeks. The current stock price of $45.15 is -0.7% below the 52-week high of $45.47, and the stock has appreciated +11.6% over the past 30 days and +13.3% over 90 days, positioning this sale near recent highs. RPRX fundamentals remain solid with $609.3M quarterly revenue, $288.2M net income, +5.1% annual growth, and a P/E of 25.95. The frequency of CFO dispositions in rapid succession, combined with sustained near-peak pricing and strong recent momentum, merits tracking of whether this reflects scheduled liquidity or a change in the executive's forward view.

CFO Terrance P. Coyne executes 6 scheduled sales totaling 243,541 shares for $10,360,814.09 under 10b5-1 plan

Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, completed 6 separate sales across three trading days (2026-02-02 through 2026-02-04) totaling 243,541 shares for $10,360,814.09 at a blended average price of $42.54, reducing his holdings from 266,426 shares to 22,885 shares, a reduction of 91.4% of his pre-transaction position. The sales were executed under a pre-arranged 10b5-1 trading plan adopted on 2025-08-08, meaning these transactions were scheduled rather than discretionary. While the scale of the position reduction is material, the structured nature of the plan and the CFO's retention of 22,885 shares post-transaction indicates an orderly, predetermined execution rather than an emergency or sentiment-driven exit.

EVP & CFO Coyne Terrance P. sold 69,582 shares at $39.35 totaling $2.7M under 10b5-1 plan

Coyne Terrance P., EVP and CFO of Royalty Pharma plc, executed 2 separate sales totaling 69,582 shares for $2,737,940.37 at a blended average price of $39.35 on 2026-01-20. This transaction reduced his holdings from 105,592 shares to 36,010 shares, representing a net reduction of 69,582 shares. The transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-08, making it a scheduled sale rather than a discretionary trade. Given the plan structure and the significant reduction in ownership position, investors should review the disclosed reasons in the Form 4 filing documentation and monitor whether additional sales are scheduled under the 10b5-1 plan terms.